Assessment of Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer

Ola H Malalah,

Published on: 2020-05-05

Abstract

Neoadjuvant systemic therapy in the treatment of breast cancer was at first employed for patients with inoperable disease. Over the past years this treatment approach has been proved to be beneficial in many other clinical scenarios including those with early stage, operable breast cancer. Neoadjuvant chemotherapy can reduce tumor burden and facilitating breast conservative surgery in selected patients without significant increase in local recurrence. The aim was to assess the pattern of pathological response in breast cancer patient in mastectomy specimens after treatment with neoadjuvant chemotherapy. Patients criteria in this study was patients with early stage or locally advanced breast cancer with or without axillary lymph node involvement and absence of distant metastasis, exposed to previous lumpectomy were excluded from the study. The patients were included from the outpatient consultation clinics in Oncology Teaching Hospital. History, physical examination, radiology and pathology reports were documented. The patients were categorized according to the indication to neoadjuvant chemotherapy, the intrinsic subtypes (according to immunohistochemistry), and the pathological response. 

Please click on the PDF to view complete abstract

scroll up